Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label brivaracetam adjunctive treatment study in pediatric epilepsy
NL-OMON50183Phase 3Withdrawn
- Sponsor
- UCB
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brivaracetam in epilepsy and Focal Onset Epilepsy, sponsored by UCB. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of treatment-emergent serious adverse events. Planned start May 2017; status: withdrawn.
02
Drugs
brivaracetam
03
Conditions
epilepsyFocal Onset Epilepsy
Beyond the preview
Go deeper on NL-OMON50183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50183.